证券代码：000597 证券简称：东北制药 公告编号：2025-075 东北制药集团股份有限公司 关于会计估计变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要提示 1.本次会计估计变更采用未来适用法进行会计处理，不会对以往各年度财务 状况和经营成果产生影响。 2.本议案无需提交公司股东会审议。 一、会计估计变更概述 东北制药集团股份有限公司（以下简称"公司"）于 2025 年 11 月 28 日召 开第十届董事会第八次会议审议通过了《关于会计估计变更的议案》，同意公司 于 2026 年 1 月 1 日起对固定资产-运输工具中的非生产用车折旧年限、年折旧率 进行变更。 （一）变更日期 （三）会计估计变更的内容 | 类别 | 变更前 | | 变更后 | | | --- | --- | --- | --- | --- | | | 使用年限（年） | 年折旧率% | 使用年限（年） | 年折旧率% | | 运输工具 | 8 | 11.88 | 5-8 | 19.00-11.88 | 二、会计估计变更对公司的影响 1 根据《企业会计准则第 28 号——会 ...

证券代码：000597 证券简称：东北制药 公告编号：2025-074 东北制药集团股份有限公司关于 变更公司注册资本、股份总数、取消监事会并 修订《公司章程》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 东北制药集团股份有限公司（以下简称"公司"）于 2025 年 11 月 28 日召 开第十届董事会第八次会议，以同意 11 票，反对 0 票，弃权 0 票，审议通过了 《关于变更公司注册资本、股份总数、取消监事会并修订〈公司章程〉的议案》。 该议案尚需提交公司股东会审议。现将相关情况公告如下： 公司 2022 年限制性股票激励计划相关事项实施后，公司对 2022 年限制性股 票激励计划所涉及的不符合条件的激励对象持有的部分或全部已获授但尚未解 除限售的限制性股票进行回购注销，注册资本由人民币 1,429,103,265 元调整为 人民币 1,427,088,265 元，股份总数由 1,429,103,265 股调整为 1,427,088,265 股。 为进一步促进公司规范运作，根据中国证券监督管理委员会发布的《关于新 <公司法>配套制度规则实施相关 ...

证券代码：000597 证券简称：东北制药 公告编号：2025-076 东北制药集团股份有限公司 2.股东会的召集人：董事会 关于召开 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 1.股东会届次：2025 年第二次临时股东会 3.会议召开的合法、合规性：本次会议的召集、召开符合《中华人民共和国 公司法》《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管 指引第1号——主板上市公司规范运作》等法律、行政法规、部门规章、规范性文 件及《公司章程》的有关规定。 4.会议时间： （1）现场会议时间：2025 年 12 月 15 日 14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 12 月 15 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所 互联网投票系统投票的具体时间为 2025 年 12 月 15 日 9:15 至 15:00 的任意时间。 5.会议的召开方式：现场表决与网络投票相结合。 一、召开会议的基本情况 2025 年 ...

证券代码：000597 证券简称：东北制药 公告编号：2025-073 东北制药集团股份有限公司 第十届监事会第五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、监事会会议召开情况 具体内容详见巨潮资讯网披露的《东北制药集团股份有限公司关于会计估计 变更的公告》（公告编号：2025-075）。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 议案二：关于变更公司注册资本、股份总数、取消监事会并修订《公司章 程》的议案 具体内容详见巨潮资讯网披露的《关于变更公司注册资本、股份总数、取消 监事会并修订〈公司章程〉的公告》（公告编号：2025-074）。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 1.东北制药集团股份有限公司（以下简称"公司"）第十届监事会第五次会 议于 2025 年 11 月 23 日发出会议通知，于 2025 年 11 月 28 日以通讯表决的方式 召开。 2.会议应参加监事 3 人，实际参加监事 3 人。 3.本次会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、 规范性文件和《东北制药集团股份有 ...

证券代码：000597 证券简称：东北制药 公告编号：2025-072 东北制药集团股份有限公司 第十届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 1.东北制药集团股份有限公司（以下简称"公司"）第十届董事会第八次会 议于 2025 年 11 月 23 日发出会议通知，于 2025 年 11 月 28 日以通讯表决的方式 召开。 2.会议应参加董事 11 人，实际参加董事 11 人。 3.本次会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、 规范性文件和《东北制药集团股份有限公司章程》的规定，会议形成的决议合法 有效。 二、董事会会议审议情况 会议审议并以记名投票表决方式通过以下议案： 表决结果：同意 11 票，反对 0 票，弃权 0 票。 本议案在提交董事会审议前，已通过董事会审计委员会审核。 议案二：关于变更公司注册资本、股份总数、取消监事会并修订《公司章 程》的议案 具体内容详见巨潮资讯网披露的《关于变更公司注册资本、股份总数、取消 监事会并修订〈公司章程〉的公告》（公告编号：2025-0 ...

Core Insights - Northeast Pharmaceutical, a subsidiary of Liaoning Fangda Group, is focusing on expanding its business in the pharmaceutical and health sectors through three key initiatives: drug research and innovation, development of health food products, and entry into the beauty industry with functional skincare products [2][3]. Group 1: Pharmaceutical Innovation - The company views research and innovation as its "lifeline" and has established a robust R&D system, successfully launching over 20 new raw materials and formulations in recent years [3]. - The recent approval of the DC-TY0801 injection for clinical trials marks a significant advancement in the company's oncology treatment portfolio, specifically targeting EGFRvIII positive recurrent or progressive high-grade glioma [3]. - The company is also expanding its pipeline with multiple tumor-targeted cell therapy products, enhancing its capabilities in the healthcare service sector [3]. Group 2: Health Food Development - Northeast Pharmaceutical is tapping into the health food market by launching a series of health-oriented biscuits, including products made from traditional Chinese medicinal ingredients [4]. - The biscuits are developed in collaboration with local universities, ensuring adherence to national food safety standards and scientific formulation [4][5]. - The product line includes various flavors designed to meet different health needs, showcasing the integration of traditional health concepts with modern food technology [4][5]. Group 3: Expansion into Beauty Industry - The company has launched a functional skincare brand, "Qifangyuan," which combines pharmaceutical standards with skincare innovation [6]. - The skincare products are developed using pharmaceutical-grade raw materials and undergo rigorous safety and efficacy testing [6]. - This move is part of a broader strategy to diversify and meet the growing demand for comprehensive health services, leveraging the company's expertise in pharmaceuticals [6].

Core Viewpoint - Northeast Pharmaceutical is focusing on innovation-driven growth and deepening its core business, achieving significant results in R&D breakthroughs and quality improvement, establishing a collaborative development pattern of "R&D innovation, stable core business profitability, and efficient asset operation" [1][2] Group 1: Innovation Drug Business Breakthrough - The company has adopted a dual-driven strategy of "innovative drugs + generic drugs," enhancing its product matrix across various fields including neurology, digestion, endocrinology, oncology, and autoimmune diseases [2] - R&D investment has significantly increased, with a 95% year-on-year growth in R&D expenses in the first three quarters of this year, particularly targeting tumor immunotherapy [2] - The approval of DCTY0801 injection for clinical trials marks a key advancement in the company's innovative drug field, filling a gap in its oncology treatment portfolio and positioning it advantageously in the glioblastoma segment [2][3] Group 2: Steady Growth of Core Business - The core business of Northeast Pharmaceutical has shown steady growth, with a 27.54% year-on-year increase in net profit attributable to the parent company in the third quarter [4] - The company holds significant positions in various segments, being a major global supplier of vitamin C raw materials, and the largest producer of phosphomycin series products [4] - The product structure has been continuously improved, enhancing market competitiveness, with offerings spanning vitamins, anti-infection drugs, reproductive hormones, and more [4] Group 3: Financial and Operational Optimization - The development of the core business has supported the optimization of the operational structure and improved financial stability, with enhanced procurement efficiency and faster capital turnover [5] - The company aims to continue improving production organization, technical breakthroughs, and cost reduction, leveraging digital tools and R&D resources to enhance management efficiency [5] - The focus on product structure and R&D pipeline will strengthen the company's sustainable development capabilities and adaptability to industry trends and market competition [5]

Core Viewpoint - The company has achieved significant results in innovation-driven development and core business enhancement, establishing a collaborative development pattern that focuses on "research and innovation breakthroughs, stable core business profitability, and efficient asset operation" [1][3] Innovation Drug Business Breakthrough - The company has received approval for clinical trials of DCTY0801 injection, targeting EGFRvIII positive recurrent or progressive high-grade glioma, marking a significant advancement in its innovative drug field [2] - The company has formed a self-research system covering cutting-edge technologies such as TCR-T and CAR-T, developing several tumor-targeted cell immunotherapy products for various cancers, indicating a broad commercialization prospect [2] Steady Growth of Core Business - The company's non-net profit attributable to shareholders increased by 27.54% year-on-year in the third quarter, attributed to continuous deepening in traditional advantageous areas and enhanced product competitiveness [3] - The company is a major global supplier of vitamin C raw materials and has a strong position in various segments, including being the largest producer of phosphomycin and a key supplier of chloramphenicol [3][4] Operational and Financial Stability - The company has improved its operational structure and financial stability, with enhanced procurement efficiency and faster capital turnover, providing strong support for future R&D investments and production operations [4] - The company plans to continue efforts in production organization, technical breakthroughs, process optimization, and cost reduction to enhance management efficiency and operational quality [4][5]

Core Insights - The article highlights the ongoing capital operations of Fang Wei, chairman of Fangda Group, particularly focusing on HNA Holding's recent financial maneuvers and Fangda Group's strategic investments across various industries [2][5][18]. Group 1: Capital Operations - HNA Holding completed a capital increase of 1.635 billion yuan to its subsidiary HNA Technology, maintaining a 68.07% stake post-increase [5]. - HNA Holding also finalized a 799 million yuan acquisition of Tianyu Flight Training, a flight training company, indicating a strategic focus on aviation [5][9]. - Fangda Group's investments include a 2.66 billion yuan increase in Chongqing Fangda Aviation International Headquarters and a 9.58 billion yuan acquisition of a 65% stake in Chongqing Medical University Affiliated Third Hospital [8][17]. Group 2: Business Performance - All five A-share companies under Fangda Group reported profitability in the first three quarters of 2025, with notable performances from Fangda Special Steel and HNA Holding [18][20]. - HNA Holding's net profit reached 2.845 billion yuan, a 30.93% increase year-on-year, recovering from previous significant losses [19][20]. - Fangda Carbon's net profit was 113 million yuan, despite a more than 50% decline, reflecting the pressures of the steel industry's low cycle [18]. Group 3: Fangda Model - The "Fangda Model" is characterized by precise asset acquisition, capital operations, and the introduction of refined management practices, which have proven effective in revitalizing struggling companies [22][23]. - Fang Wei's approach includes maintaining employee stability and morale through financial incentives and a commitment to not reducing staff or salaries [22][23]. - The model's effectiveness is evident in the successful turnaround of previously distressed companies, showcasing its resilience and adaptability in various sectors [22][23].

Core Insights - The company is focusing on a "Big Push in Q4" initiative to efficiently coordinate production, supply, and sales, aiming to meet annual targets [1] - In October, the company achieved significant production efficiency and cost optimization, exceeding production plans for core products [1] - The sales strategy is adapting to market challenges by enhancing customer development and expanding sales channels, particularly in the raw materials and formulations sectors [2] - A collaborative support system is in place to ensure supply stability, cost reduction, and quality assurance, contributing to the company's confidence in achieving its annual goals [3] Production Efficiency and Cost Reduction - The production system is guided by principles of "full load, high efficiency, and low cost," implementing a "weekly scheduling and daily tracking" control mechanism [1] - Various plants have made significant progress in cost reduction and efficiency improvement through process optimization and energy management [1] - The 202 plant has achieved breakthroughs in both new project development and existing project optimization, enhancing production efficiency for key products [1] Sales Strategy and Market Expansion - The sales system is closely monitoring market trends and adjusting strategies to address intensified competition and demand fluctuations [2] - The company is actively participating in international exhibitions to expand sales channels and improve customer engagement [2] - New business initiatives, such as health food and cosmetics, are being accelerated to diversify revenue streams [2] Collaborative Support System - The support system emphasizes "strong service, supply assurance, and baseline protection," fostering cross-departmental collaboration [3] - The procurement department is ensuring stable supply through multi-channel strategies, while energy management is focused on cost reduction [3] - Quality inspection processes are strictly enforced to maintain product quality, contributing to a robust operational framework [3]